Julaeha, - and Umi Athiyah, - and Josephine P Ayuningtyas, - and Verra Yuliana, - and Andi Hermansyah, - (2021) Metabolic Syndrome Risk Associated with Atypical Antipsychotic Medication: A Case Report. Journal of Drug Delivery and Therapeutic, 11 (1). pp. 77-79. ISSN 2250-1177

	Text (FULLTEXT) Bukti Artikel C-24.pdf Download (2MB)
	Text (KUALITAS KARIL) Bukti Validasi dan Penilaian Karil C-24.pdf Download (390kB)
	Text (SIMILARITY) Bukti Similarity C-24.pdf Download (855kB)
	Text (KORESPONDENSI) Bukti Korespondensi C-24.pdf Download (781kB)

Abstract

People with schizophrenia are vulnerable group suffer from metabolic syndrome events. Atypical antipsychotics associated with weight gain, insulin resistance, and profile lipid abnormalities. The present case was 32-year-old man schizophrenia outpatient had experienced metabolic syndrome side effects. Metabolic syndrome characterized by central obesity, hyperglicemia, hypertriglyceridemia, low High Density Lipoprotein (HDL) cholesterol level, and several months feel an increase in appetite. Metabolic syndrome events might be associated with long-term atypical antipsychotics consuming and tobacco use. As pharmacists, We advised the patient to referral primary healthcare service for managing metabolic syndrome side effects. Pharmacists intervention through education and metabolic syndrome screening program have positive impacts on lifestyle modification such as decreasing number of cigarette consumption and caffeine intake, also increasing physical activity.

Actions (login required)

View Item